{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "priceEpsCurrentYear": -5.688889, "sharesOutstanding": 166134000, "bookValue": 0.872, "fiftyDayAverage": 2.8346, "fiftyDayAverageChange": -0.27460003, "fiftyDayAverageChangePercent": -0.09687435, "twoHundredDayAverage": 2.54735, "twoHundredDayAverageChange": 0.012650013, "twoHundredDayAverageChangePercent": 0.0049659503, "marketCap": 442045440, "forwardPE": -4.7407403, "priceToBook": 2.9357798, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "exchange": "NMS", "shortName": "Arbutus Biopharma Corporation", "longName": "Arbutus Biopharma Corporation", "messageBoardId": "finmb_34160168", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "regularMarketChangePercent": 0.78740084, "regularMarketPrice": 2.56, "firstTradeDateMilliseconds": 1185456600000, "priceHint": 4, "preMarketChange": 0.0, "preMarketChangePercent": 0.0, "preMarketTime": 1684233699, "preMarketPrice": 2.56, "regularMarketChange": 0.01999998, "regularMarketTime": 1684180804, "regularMarketDayHigh": 2.63, "regularMarketDayRange": "2.52 - 2.63", "regularMarketDayLow": 2.52, "regularMarketVolume": 417569, "regularMarketPreviousClose": 2.54, "bid": 0.0, "ask": 0.0, "bidSize": 32, "askSize": 40, "fullExchangeName": "NasdaqGS", "financialCurrency": "USD", "regularMarketOpen": 2.53, "averageDailyVolume3Month": 963148, "averageDailyVolume10Day": 605030, "fiftyTwoWeekLowChange": 0.7099999, "fiftyTwoWeekLowChangePercent": 0.38378373, "fiftyTwoWeekRange": "1.85 - 3.15", "fiftyTwoWeekHighChange": -0.59000015, "fiftyTwoWeekHighChangePercent": -0.18730164, "fiftyTwoWeekLow": 1.85, "fiftyTwoWeekHigh": 3.15, "earningsTimestamp": 1683204300, "earningsTimestampStart": 1690975800, "earningsTimestampEnd": 1691407800, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.43, "epsForward": -0.54, "epsCurrentYear": -0.45, "displayName": "Arbutus Biopharma", "symbol": "ABUS"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "701 Veterans Circle", "city": "Warminster", "state": "PA", "zip": "18974", "country": "United States", "phone": "267 469 0914", "fax": "267 282 0411", "website": "https://www.arbutusbio.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.", "fullTimeEmployees": 96, "companyOfficers": [{"maxAge": 1, "name": "Mr. William H. Collier", "age": 61, "title": "Pres, CEO & Director", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 933011, "fmt": "933.01k", "longFmt": "933,011"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 145950, "fmt": "145.95k", "longFmt": "145,950"}}, {"maxAge": 1, "name": "Mr. Michael J. McElhaugh", "age": 48, "title": "COO & Chief Bus. Officer", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": {"raw": 606625, "fmt": "606.62k", "longFmt": "606,625"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Michael J. Sofia Ph.D.", "age": 64, "title": "Chief Scientific Officer", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": {"raw": 628435, "fmt": "628.43k", "longFmt": "628,435"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. David C. Hastings CPA", "age": 61, "title": "CFO & Chief Accounting Officer", "yearBorn": 1961, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lisa M. Caperelli", "title": "VP of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Elizabeth  Howard J.D., Ph.D.", "age": 68, "title": "Exec. VP, Gen. Counsel, Chief Compliance Officer & Sec.", "yearBorn": 1954, "fiscalYear": 2017, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C.", "age": 71, "title": "Sec.", "yearBorn": 1951, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 2, "boardRisk": 5, "compensationRisk": 6, "shareHolderRightsRisk": 9, "overallRisk": 5, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}